Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prestige Brands’ OTC Revenue Climbs With Boost In Advertising

This article was originally published in The Tan Sheet

Executive Summary

Prestige CEO Mannelly attributes the success of Clear Eyes, Chloraseptic, Compound W and Little Remedies to a $1 million increase in advertising and promotions. The OTC division’s net revenue soar 55.7% to $79.2 million.

You may also be interested in...



People In Brief

Williams stars in Clear Eyes campaign; industry veteran Brown joins Innovus as CFO; Mannatech makes promotions, addition; Loew heads Sanofi’s European commercial operations; Bayer HealthCare moves Schubmehl to CIO; more People In Brief.

People In Brief

Williams stars in Clear Eyes campaign; industry veteran Brown joins Innovus as CFO; Mannatech makes promotions, addition; Loew heads Sanofi’s European commercial operations; Bayer HealthCare moves Schubmehl to CIO; more People In Brief.

In Brief

Prestige Brands gains from acquisitions

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS105414

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel